Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

ARWR stock hub

Arrowhead Pharmaceuticals, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

ARWRis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

10.2B

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

ARWR

In the news

Latest news · ARWR

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-42.4

P25 -105.6P50 -46.5P75 -3.1

ROIC-81.2

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All ARWR market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

225

Groups with data

Currency

USD

Showing 225 of 225 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0000879407
Company name	Arrowhead Pharmaceuticals, Inc.
Country	United States
Country code	US
Cusip	04280A100
Employees	711
Employees Change	102%
Employees Change Percent	16.75
Enterprise value	$9.8B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	1993-06-16
Isin	US04280A1007
Last refreshed	2026-05-10
Market cap	$10.2B
Market cap category	Large-Cap
Price	$72.69
Price currency	USD
Rev Per Employee	874,836.85x
Sector	Healthcare
Sic	2834
Symbol	ARWR
Website	https://arrowheadpharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-2.94%
EV Sales Forward	59.26x
EV/Sales	15.82x
FCF yield	-0.5%
P/B ratio	16.64x
P/S ratio	16.46x
PS Forward	61.65x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	-35.67%
EBITDA Margin	-31.6%
Gross margin	100%
Gross Profit	$622M
Gross Profit Growth	14.09%
Gross Profit Growth Q	-86.41%
Gross Profit Growth3 Y	31.62%
Gross Profit Growth5 Y	47.49%
Net Income	$-300.9M
Net Income Growth Years	1%
Pretax Margin	-40.56%
Profit Margin	-48.38%
Profit Per Employee	$-423,221
ROA	-7.22
Roa5y	-16.64
ROCE	-11.25
ROE	-42.37
Roe5y	-76.13
ROIC	-81.18
Roic5y	-116.1

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	29.25%
Cagr15y	18.22%
Cagr1y	457.24%
Cagr20y	0.01%
Cagr3y	20.65%
Cagr5y	1.83%
EPS Growth Years	1
FCF Growth Q	-82%
OCF Growth Q	-81.65%
Revenue Growth	14.09x
Revenue Growth Q	-86.41x
Revenue Growth Years	1x
Revenue Growth3 Y	31.62x
Revenue Growth5 Y	47.49x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.32
Assets	$2.3B
Cash	$1.8B
Current Assets	$1.8B
Current Liabilities	$295.2M
Debt	$1.4B
Debt Equity	$2.31
Equity	$598.9M
Interest Coverage	-2.4
Liabilities	$1.7B
Long Term Assets	$428.5M
Long Term Liabilities	$1.4B
Net Cash	$398.4M
Net Cash By Market Cap	$3.89
Net Cash Growth	12.29%
Net Debt Equity	$-0.67
Tangible Book Value	$608M
Tangible Book Value Per Share	$4.32
WACC	10.62

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	6.23
Net Working Capital	$-179.4M
Quick ratio	6.09
Working Capital	$1.5B
Working Capital Turnover	$0.51

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-9.83%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	1,200.36%
1Y total return	456.59%
200-day SMA	50.08
3Y total return	75.67%
50-day SMA	65.06
50-day SMA vs 200-day SMA	50over200
5Y total return	9.51%
All Time High	150
All Time High Change	-51.54%
All Time High Date	2004-01-22
All Time Low	1.2
All Time Low Change	5,957.5%
All Time Low Date	2016-12-21
ATR	3.6
Beta	1.29
Beta1y	2
Beta2y	2.34
Ch YTD	9.49
High	77.92
High52	79.48
High52 Date	2026-05-06
High52ch	-8.54%
Low	72.61
Low52	12.44
Low52 Date	2025-05-08
Low52ch	484.33%
Ma50ch	11.73%
Premarket Change Percent	-0.96
Premarket Price	$77.2
Premarket Volume	1,816
Price vs 200-day SMA	45.15%
RSI	53.87
RSI Monthly	73.42
RSI Weekly	67.97
Sharpe ratio	2.89x
Sortino ratio	5.41
Total Return	-9.83%
Tr YTD	9.49
Tr15y	1,132.03%
Tr1m	18.81%
Tr1w	-2.83%
Tr3m	12.66%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	11
Analyst Count Top	6
Analyst Price Target Top	$90.33
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-1.14
Earnings Revenue Estimate	69,266,760x
Earnings Revenue Estimate Growth	-87.24x
Operating Income	$-221.9M
Operating margin	-35.67
Price target	$84.45
Price Target Change	$16.18
Price Target Change Top	$24.27

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	122,037,310%
Float Percent	86.64%
Net Borrowing	575,754,000
Shares Insiders	3.3%
Shares Institutions	73.48%
Shares Out	140,857,021
Shares Qo Q	1.22%
Shares Yo Y	9.83%
Short Float	9.84%
Short Ratio	5.82
Short Shares	8.53

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-119M
Average Volume	1,890,127.8x
Bv Per Share	4.37
CAPEX	$-14.6M
Ch10y	1,200.4
Ch15y	1,132
Ch1m	18.81
Ch1w	-2.83
Ch1y	456.6
Ch20y	0.12
Ch3m	12.66
Ch3y	75.67
Ch5y	9.51
Ch6m	85.29
Change	-6.75%
Change From Open	-4.98
Close	77.95
Days Gap	-1.86
Depreciation Amortization	25,367,000
Dollar Volume	196,277,756.1
Earnings Date	2026-05-07
Earnings Time	amc
EBIT	$-221.9M
EBITDA	$-196.5M
EPS	$-2.17
F Score	2
FCF	$-50.9M
FCF EV Yield	-0.52x
FCF Per Share	$-0.36
Financing CF	741,957,000
Fiscal Year End	September
Founded	2,003
Income Tax	$19.6M
Investing CF	-704,015,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-07
Last Report Date	2026-03-31
Last Split Date	2011-11-17
Last Split Type	Reverse
Last10k Filing Date	2025-11-25
Ma150	58.77
Ma150ch	23.69%
Ma20	72.26
Ma20ch	0.6%
Net CF	2,808,000
Next Earnings Date	2026-08-06
Open	76.5
Optionable	Yes
Position In Range	1.51
Post Close	72.69
Postmarket Change Percent	0.58
Postmarket Price	$73.11
Ppne	417,616,000
Pre Close	77.95
Price Date	2026-05-08
Ptbv Ratio	16.84
Relative Volume	1.43x
Revenue	622,009,000x
SBC By Revenue	10.96x
Share Based Comp	68,171,000
Tax By Revenue	3.15x
Tr20y	0.12%
Tr6m	85.29%
Us State	California
Volume	2,700,203
Z Score	1.53

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does ARWR pay a dividend?

Capital-return profile for this ticker.

Performance

ARWR stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns ARWR?

Insider, institutional, and short-interest positioning.

Institutional ownership

+73.5%

Float: +86.6% of shares outstanding

Insider ownership

+3.3%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

ARWR momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

53.9

Neutral momentum band

Price vs 200-day MA

+45.1%

50/200-day relationship not available

Beta (5Y)

1.29

More volatile than the market

Sharpe ratio

2.89

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About ARWR

Hub-level FAQ points readers to the deeper analysis pages.

What is the current ARWR stock rating?

Arrowhead Pharmaceuticals, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full ARWR analysis?

The full report lives at /stocks/ARWR/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for ARWR?

The latest report frames ARWR around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the ARWR page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.